PMID- 17464718
OWN - NLM
STAT- MEDLINE
DCOM- 20070703
LR  - 20131121
IS  - 0004-8674 (Print)
IS  - 0004-8674 (Linking)
VI  - 41
IP  - 4
DP  - 2007 Apr
TI  - Changes in brain-derived neurotrophic factor following treatment with 
      mifepristone in bipolar disorder and schizophrenia.
PG  - 321-6
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is stress-responsive and has 
      been implicated in a number of disparate neuropsychiatric disorders. 
      Glucocorticoid antagonists have been shown to have beneficial effects on mood and 
      cognitive function in bipolar disorder but not in schizophrenia. The aim of the 
      present study was to investigate BDNF levels in patients with bipolar disorder 
      and schizophrenia before and after treatment with the glucocorticoid receptor 
      antagonist mifepristone. METHODS: Peripheral BDNF levels were measured in 
      patients with bipolar disorder (n=20), schizophrenia (n=20) and 14 matched 
      healthy controls following 7 days of adjunctive mifepristone (600 mg day(-1)) 
      treatment in a double-blind, placebo-controlled crossover design study. RESULTS: 
      Baseline BDNF values were similar in both patient groups and in healthy controls. 
      Following treatment with mifepristone, cortisol levels were significantly 
      increased and BDNF levels decreased in both schizophrenia and bipolar disorder. A 
      significant correlation existed between change in cortisol level and change in 
      BDNF levels following mifepristone treatment in schizophrenia, but not in bipolar 
      disorder. CONCLUSION: Differing BDNF responses to increasing cortisol levels 
      between patients with schizophrenia and with bipolar disorder may reflect 
      underlying pathophysiological mechanisms.
FAU - Mackin, Paul
AU  - Mackin P
AD  - School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon 
      Tyne, Leazes Wing (Psychiatry), Royal Victoria Infirmary, Newcastle upon Tyne, 
      NE1 4LP, UK. paul.mackin@ncl.ac.uk
FAU - Gallagher, Peter
AU  - Gallagher P
FAU - Watson, Stuart
AU  - Watson S
FAU - Young, Allan H
AU  - Young AH
FAU - Ferrier, I Nicol
AU  - Ferrier IN
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aust N Z J Psychiatry
JT  - The Australian and New Zealand journal of psychiatry
JID - 0111052
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hormone Antagonists)
RN  - 320T6RNW1F (Mifepristone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Affect/drug effects
MH  - Bipolar Disorder/*drug therapy/physiopathology
MH  - Brain-Derived Neurotrophic Factor/*drug effects
MH  - Cognition/drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Hormone Antagonists/administration & dosage/*pharmacology/*therapeutic use
MH  - Humans
MH  - Hydrocortisone/metabolism
MH  - Hypothalamo-Hypophyseal System/drug effects
MH  - Male
MH  - Middle Aged
MH  - Mifepristone/administration & dosage/*pharmacology/*therapeutic use
MH  - Pituitary-Adrenal System/drug effects
MH  - Schizophrenia/*drug therapy/physiopathology
EDAT- 2007/04/28 09:00
MHDA- 2007/07/04 09:00
CRDT- 2007/04/28 09:00
PHST- 2007/04/28 09:00 [pubmed]
PHST- 2007/07/04 09:00 [medline]
PHST- 2007/04/28 09:00 [entrez]
AID - 773322843 [pii]
AID - 10.1080/00048670701213211 [doi]
PST - ppublish
SO  - Aust N Z J Psychiatry. 2007 Apr;41(4):321-6. doi: 10.1080/00048670701213211.